TY - JOUR
T1 - IFN-α enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity
AU - Sikora, Andrew G.
AU - Jaffarzad, Nina
AU - Hailemichael, Yared
AU - Gelbard, Alexander
AU - Stonier, Spencer W.
AU - Schluns, Kimberly S.
AU - Frasca, Loredana
AU - Lou, Yanyan
AU - Liu, Chengwen
AU - Andersson, Helen A.
AU - Hwu, Patrick
AU - Overwijk, Willem W.
PY - 2009/6/15
Y1 - 2009/6/15
N2 - Type I IFNs, including IFN-α, enhance Ag presentation and promote the expansion, survival, and effector function of CD8+ CTL during viral infection. Because these are ideal characteristics for a vaccine adjuvant, we examined the efficacy and mechanism of exogenous IFN-α as an adjuvant for antimelanoma peptide vaccination. We studied the expansion of pmel-1 transgenic CD8+ T cells specific for the gp100 melanocyte differentiation Ag after vaccination of mice with gp10025-33 peptide in IFA. IFN-α synergized with peptide vaccination in a dose-dependent manner by boosting relative and absolute numbers of gp100-specific T cells that suppressed B16 melanoma growth. IFN-α dramatically increased the accumulation of gp100-specific, IFN-α-secreting, CD8+ T cells in the tumor through reduced apoptosis and enhanced proliferation of Ag-specific CD8 + T cells. IFN-α treatment also greatly increased the long-term maintenance of pmel-1 CD8+ T cells with an effector memory phenotype, a process that required expression of IFN-α receptor on the T cells and IL-15 in the host. These results demonstrate the efficacy of IFN-α as an adjuvant for peptide vaccination, give insight into its mechanism of action, and provide a rationale for clinical trials in which vaccination is combined with standard-of-care IFN-α therapy for melanoma.
AB - Type I IFNs, including IFN-α, enhance Ag presentation and promote the expansion, survival, and effector function of CD8+ CTL during viral infection. Because these are ideal characteristics for a vaccine adjuvant, we examined the efficacy and mechanism of exogenous IFN-α as an adjuvant for antimelanoma peptide vaccination. We studied the expansion of pmel-1 transgenic CD8+ T cells specific for the gp100 melanocyte differentiation Ag after vaccination of mice with gp10025-33 peptide in IFA. IFN-α synergized with peptide vaccination in a dose-dependent manner by boosting relative and absolute numbers of gp100-specific T cells that suppressed B16 melanoma growth. IFN-α dramatically increased the accumulation of gp100-specific, IFN-α-secreting, CD8+ T cells in the tumor through reduced apoptosis and enhanced proliferation of Ag-specific CD8 + T cells. IFN-α treatment also greatly increased the long-term maintenance of pmel-1 CD8+ T cells with an effector memory phenotype, a process that required expression of IFN-α receptor on the T cells and IL-15 in the host. These results demonstrate the efficacy of IFN-α as an adjuvant for peptide vaccination, give insight into its mechanism of action, and provide a rationale for clinical trials in which vaccination is combined with standard-of-care IFN-α therapy for melanoma.
UR - http://www.scopus.com/inward/record.url?scp=67649220219&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67649220219&partnerID=8YFLogxK
U2 - 10.4049/jimmunol.0802982
DO - 10.4049/jimmunol.0802982
M3 - Article
C2 - 19494262
AN - SCOPUS:67649220219
SN - 0022-1767
VL - 182
SP - 7398
EP - 7407
JO - Journal of Immunology
JF - Journal of Immunology
IS - 12
ER -